

## *Innovative medicines & oncology practice during covid.*

Abdalla Abotaleb

WHO Project Manager & Founder of MENA Network of Biological Stakeholders, Egypt



### *Abstract*

**O**bjectives: Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient's outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during these hard times. Previous objectives raised many questions about nature of treatment protocols and policies should be implemented during (COVID -19) Pandemic and how innovative medicines can achieve the previous objectives. At MENA countries (Algeria, Morocco, Egypt, Lebanon, KSA, UAE and Turkey)

**METHODS:** Integration analysis between International guidelines like (ESMO, ASCO, WHO) and local guidelines local survives with local oncologist at previous countries plus quality of life questionnaires for the patients were conducted. Cost Analysis from health systems for all oncology expenditures. One way sensitivity analysis was conducted for all parameters affecting on practice adaptation to ensure validity and accuracy

**RESULTS:** Innovative medicines had positive impact on Enhancement of patient's outcomes and resources utilization via implementation efficient Periodization criteria as following

**CONCLUSION:** Innovative medicines protocols changed the oncology practice during COVID -19 through Dynamic & efficient prioritization criteria which led to patient's outcomes (quality of life – economic value – clinical effectiveness) enhancement plus Resources utilization

**Key words:** Policy analysis, Innovative Treatments, cancer, COVID-19

### *Biography:*

Abdalla Abotaleb is one of the most profound experts in healthcare policy and regulations in the MENA region His expertise extend from HTA & Reimbursement policies , policy analysis to regulatory and supply chain strategies in the public sector. He has been involved in the fields of health economics, Health policy reforming and reimbursement polices for 15 years, with experience across the pharmaceutical, biologicals and vaccines. And now works for WHO as a project manager at health care reforming area.

### *Speaker Publications:*

1. "Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force."
2. "Pdb40-impact of dapagliflozin on reducing economic burden of type 2 diabetes &enhancement patient's outcomes at countries with high incidence of diabetes egypt case".
3. "Analysis reimbursement & public spending policies for immunological diseases at low and middle income countries"
4. "Economic Burden of HCC And The Need Of Innovative Treatments"

[2<sup>nd</sup> Global Meeting on Oncology and Radiology;](#)  
Webinar- December 10, 2020

### *Abstract Citation:*

Abdalla Abotaleb, Innovative Medicines & oncology practice during COVID, Radiology and Oncology 2020, 2<sup>nd</sup> Global Meeting on Oncology and Radiology; Webinar- December 10, 2020

(<https://radiology-oncology.annualcongress.com/>)

